The first TOP10 generic drug companies are released!

The first generic drug has always been the focus of the R&D layout of domestic pharmaceutical companies, and has gradually entered a period of intensive approval in recent years
.
According to the data of Minet.
com, in the past three years (2019-2021), more than 150 first imitations (including the first imitations of dosage forms) have been approved for marketing, and in terms of the time of approval, the trend is increasing year by year
.
Among the TOP10 companies, Sino Biopharmaceuticals and Hengrui Medicine have both obtained 10 or more first imitators, and Qilu Pharmaceutical and Hansoh Pharma are tied for third place with 9 first imitators
.
Over 150 first generic drugs cover 13 major categories of treatment, focusing on nervous system drugs, digestive system and metabolizing drugs, anti-tumor and immunomodulatory agents; in terms of route of administration, inhalants, sustained and controlled release preparations, eye drops, etc.
Barrier dosage forms have product approvals
.
In the past 3 years, the first imitation number TOP10 enterprises have been approved Source: Minet MED2.
0 China Drug Evaluation Database Chia Tai Tianqing "King of the first imitation" is well deserved, Hengrui has entered the harvest period for nearly 3 years, China Biopharmaceuticals has More than 50 generic drugs have been approved for listing, 16 are the first imitations, leading domestic enterprises, of which 14 were won by Chia Tai Tianqing Pharmaceutical, and the "King of First Imitations" is well deserved
.
According to data from Minet.
com, more than 10 of the newly classified generic drugs reported by Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
that have not yet been approved have not been approved for the first time
.
The 16 first copies cover 9 therapeutic categories, focusing on anti-tumor and immunomodulatory agents
.
A variety of blockbuster varieties with over US$1 billion in the world, including rivaroxaban, sitagliptin, pomalidomide, tofacitinib, emtricitabine, tenofovir, dabigatran etexilate, Thioxetine, lenvatinib, etc.
, the global sales of original research products in 2020 will exceed $7 billion, $3 billion, $3 billion, $2 billion, $1 billion, $1 billion, $1 billion, $1 billion etc.

_ As the "first brother of innovative drugs" in China, Hengrui Medicine puts its main energy, financial resources and manpower on the research and development and internationalization of innovative drugs, but imitating high-profit products that have not been imitated is also the company's development strategy, including the first imitation
.
In the past 3 years, the company has more than 20 generic drugs approved for listing, of which 10 are the first imitations, and 5 are approved for listing in 2021, leading other domestic companies.

.
Among the newly classified generic drugs that have not yet been approved for production, more than 10 have not yet been approved for the first generic
.
5 of the 10 first imitations are injections, all of which are the first in China to be approved, filling the market gap; 1 is eye drops, and the original research products will be available in Chinese urban public hospitals, county-level public hospitals, and urban community centers in the first half of 2021.
And township health centers (referred to as Chinese public medical institutions), the terminal sales growth rate is close to 300%; among the oral normal-release dosage forms, the global sales of Otsuka Pharmaceutical's tolvaptan in 2020 will exceed 1 billion US dollars
.
9 first imitations! Qilu Pharmaceutical and Hansoh Pharmaceutical tied for the third place.
Relying on the abundant generic drug clusters, Qilu Pharmaceutical has long been ahead of other domestic pharmaceutical companies in terms of the number of approved varieties, and has also gained a lot in the first five batches of centralized procurement
.
In the past 3 years, Qilu Pharmaceutical has more than 50 generic drugs approved for marketing, of which 9 are the first generic drugs, and 4 will be approved for marketing in 2021
.
Among the newly classified generic drugs that have not yet been approved for production, more than 10 have not yet been approved for the first generic
.
Only 1 of the 9 first imitations is an injection.
The sales of the original products in public medical institutions in China will exceed 200 million yuan in 2020, a year-on-year increase of more than 1,000%; among the oral preparations, the global sales of palbociclib will exceed 5 billion in 2020.
USD, trimetazidine hydrochloride sustained-release tablets and olanzapine orally disintegrating tablets are both new dosage forms
.
The global sales of the first imitation is also a key direction of Hansoh Pharmaceutical.
In the past three years, the company has approved 20 generic drugs for marketing, of which 9 are first imitations
.
Among the newly classified generic drugs that have not yet been approved for production, there are 7 generic drugs that have not been approved for the first time
.
Among the 9 approved first imitations, many are star drugs with over US$1 billion in the world, including apixaban, enzalutamide, empagliflozin, paliperidone (including injections and sustained-release tablets) , Vildagliptin, etc.
The global sales of original research products in 2020 will exceed US$10 billion, US$4 billion, US$3 billion, US$3 billion, and US$1 billion, respectively
.
Kelun, Renfu, Jianjianyuan.
.
.
Focusing on the leading enterprise of "big infusion" in the advantageous field Kelun Pharmaceutical, more than 40 generic drugs have been approved for production in the past three years, and injections account for "half of the country", of which 6 are first imitation
.
Among the varieties under review for production/clinical applications under the new classification, more than 20 have not yet been approved for the first imitation in China
.
5 of the 6 first imitations are injections, compound amino acid (15AA-II)/glucose (10%) electrolyte injection, amino acid (16)/glucose (48%) electrolyte injection are parenteral nutrition double-chamber bags, The original research has not been approved for import; ceftazidime/glucose injection for injection is the first product on the market on the company's powder-liquid dual-chamber bag platform
.
In the past three years, Renfu Pharmaceuticals has approved the production of more than 10 generic drugs, mainly neurological drugs
.
Among the 4 first imitations, Bupropion Hydrochloride Sustained-Release Tablet (II) is a Bupropion Hydrochloride Sustained-Release Tablet Membrane Controlled-Release Tablet, which is used to treat depression; Alfen/Tai/Ni injection is short-acting and strong.
Analgesics, the original research has not yet been approved for import; Midazolam oral solution is a sedative and hypnotic drug targeted at the pediatric population, filling the gap of domestic midazolam oral solution dosage forms
.
Inhalation is the key area of ​​health yuan.
In the past 3 years, the company has more than 10 generic drugs (4 inhalants) approved for production, of which 4 are the first generics (2 inhalants), and levalbuterol hydrochloride inhalation solution fills the market gap , Omega-3 fish oil medium/long-chain fat emulsion injection is the first domestic fat emulsion injection product with fish oil as the main raw material, and dantrolene sodium for injection is a rare disease drug
.
Source: Mi Intranet database, announcements of listed companies, etc.